TP53 and cancer: Nevertheless, our analysis suggests that p53 derepression of L1 through direct binding of the genomic L1 5’ UTR (previously demonstrated in vitro33,39,40) is likely to be somatically active across tissues and significantly mutagenically disrupted in vivo in cancers.